genital herpes, which is carried by an estimated 55 million Americans." Vical, San Diego: technology.newscientist.com "[...] Michal Margalith at Vical, a biopharmaceutical company based in San Diego, says he and colleagues have developed an HSV-2 vaccine using the emerging technology of DNA vaccines." Antigenics, AG-707: www.antigenics.com AG-707 (rh-HSP70-PC) is an investigational therapeutic vaccine designed to target the virus that causes genital herpes (herpes simplex virus type 2, ...